CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 2003; 53:292
doi: 10.3322/canjclin.53.5.292
© 2003 American Cancer Society
This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrow Freely available CME: Take the course for this article:
 Keratinocyte Carcinoma
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Albert, M. R.
Right arrow Articles by Weinstock, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Albert, M. R.
Right arrow Articles by Weinstock, M. A.

Keratinocyte Carcinoma

Michael R. Albert, MD and Martin A. Weinstock, MD, PhD


Dr. Albert is Instructor, Department of Dermatology, Brown University and Staff Dermatologist, Rhode Island Hospital, Providence, RI.
Dr. Weinstock is Professor, Department of Dermatology, Brown University, Chief of Dermatology, VA Medical Center, and Staff Dermatologist, Rhode Island Hospital, Providence, RI

Keratinocyte carcinoma is by far the most common cancer in the United States. Basal cell carcinomas and squamous cell carcinomas account for approximately 80% and 20% of cases of KC, respectively. The term nonmelanoma skin cancer is commonly used to refer to squamous cell carcinomas and basal cell carcinomas; however, other types of nonmelanoma skin cancer, such as adnexal tumors and sarcomas, are less common and differ in their cell type, behavior, and epidemiologic features from KC.1 Primary care clinicians are well positioned to diagnose KC and to educate patients about preventive measures such as sun protection and self-examination. Here we review epidemiologic data and strategies for prevention, diagnosis, and clinical management of KC.




This article has been cited by other articles:


Home page
 CarcinogenesisHome page
H. Rebel, N. Kram, A. Westerman, S. Banus, H. J. van Kranen, and F. R. de Gruijl
Relationship between UV-induced mutant p53 patches and skin tumours, analysed by mutation spectra and by induction kinetics in various DNA-repair-deficient mice
Carcinogenesis, December 1, 2005; 26(12): 2123 - 2130.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. Marwaha, Y.-H. Chen, E. Helms, S. Arad, H. Inoue, E. Bord, R. Kishore, R. D. Sarkissian, B. A. Gilchrest, and D. A. Goukassian
T-oligo Treatment Decreases Constitutive and UVB-induced COX-2 Levels through p53- and NF{kappa}B-dependent Repression of the COX-2 Promoter
J. Biol. Chem., September 16, 2005; 280(37): 32379 - 32388.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. W. Park, M. N. Younes, S. A. Jasser, O. G. Yigitbasi, G. Zhou, C. D. Bucana, B. N. Bekele, and J. N. Myers
AEE788, a Dual Tyrosine Kinase Receptor Inhibitor, Induces Endothelial Cell Apoptosis in Human Cutaneous Squamous Cell Carcinoma Xenografts in Nude Mice
Clin. Cancer Res., March 1, 2005; 11(5): 1963 - 1973.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by American Cancer Society.